Traduction de «Essai de lutte en champ » (Français → Anglais) :

field control trial

confined research field trial program

Electromagnetic Compatibility (EMC) – Part 4-3: Testing and Measurement Techniques – Radiated, Radio-Frequency, Electromagnetic Field Immunity Test

experimental field | test field

If tests are made using the methods described in Part 8, the immunity test reference levels shall be 48 volts/m for the 150 mm stripline testing method, 12 volts/m for the 800 mm stripline testing method, 60 volts/m for the transverse electromagnetic mode (TEM) cell testing method, 48 mA for the bulk current injection (BCI) testing method and 24 volts/m for the free field testing method.

During the calibration phase of the substitution method (prior to a vehicle being introduced into the test area), the field strength in at least 80 % of the calibration steps shall not be less than 50 % of the nominal field strength, at the following locations:

8.5.1. During the calibration phase of the substitution method (prior to an ESA under test being introduced into the test area), the field strength shall not be less than 50 % of the nominal field strength 0,5 ± 0,05 m either side of the reference point on a line parallel to the edge of the ground plane nearest to the antenna and passing through the reference point.

Following that report, there are fundamental issues to be taken into consideration for a second European and Developing Countries Clinical Trials Partnership Programme (''EDCTP2 Programme''): the current scope of EDCTP1 needs to be amended and extended; the capabilities in developing countries for the sound conduct and management of clinical trials should, where necessary, be further developed and strengthened, in particular the role and development of ethical review committees and the corresponding regulatory environment, the coordination, collaboration and, where appropriate, integration of European national programmes should be furth ...[+++]er improved; collaboration with other major public and private partners , including the pharmaceutical industry, and public-private partnerships such as the Product Development Partnerships (‘PDPs’), civil society, non-governmental organisations and foundations, need to be strengthened and extended; there should be clear and transparent rules of governance; synergies with European external policy actions should be developed specifically with Union development assistance; co-funding rules should be clarified and simplified; and monitoring tools need to be strengthened.